跳转至内容
Merck
CN

T-039

Supelco

Topiramate solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C12H21NO8S
化学文摘社编号:
97240-79-4
分子量:
339.36
EC 号:
200-659-6
UNSPSC代码:
41116107
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

质量水平

300

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

InChI key

KJADKKWYZYXHBB-XBWDGYHZSA-N

基因信息

human ... CA2(760), CA4(762), GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879), GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893), GRIK1(2897), GRIK2(2898), GRIK3(2899), GRIK4(2900), GRIK5(2901), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

相关类别

一般描述

A certified solution standard suitable for use in LC/MS or GC/MS applications for pharmaceutical research, clinical toxicology, or forensic testing.  Topiramate, sold under trade name Topamax®, is an antiepileptic drug used for treatment of seizures. Topiramate in combination with the stimulant phentermine constitute the active compounds in the new weight lose drug Qsymia®.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Qsymia is a registered trademark of Vivus, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Topamax is a registered trademark of Johnson & Johnson

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

J M Riffitts et al.
Journal of pharmaceutical and biomedical analysis, 19(3-4), 363-371 (2000-03-07)
An accurate and robust method involving liquid liquid extraction and capillary gas chromatographic (GC) assay with nitrogen phosphorus detection (NPD) was developed and validated for the quantitative determination of topiramate [2,3:4,5-bis-O-(-1-methylethylidene)-beta-D-fructopyranose sulfamate], Topamax, an anticonvulsant drug, in human plasma, urine
William Timothy Garvey
Expert opinion on drug safety, 12(5), 741-756 (2013-06-07)
Weight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction
Steve S Chung et al.
Epilepsia, 55(7), 1077-1087 (2014-06-07)
To evaluate the efficacy and safety of USL255, Qudexy(™) XR (topiramate) extended-release capsules, as an adjunctive treatment for refractory partial-onset seizures (POS) in adults taking one to three concomitant antiepileptic drugs. In this global phase III study (PREVAIL; NCT01142193), 249
Annie M Clark et al.
Epilepsia, 55(7), 1069-1076 (2014-05-28)
Evaluate the pharmacokinetics (PK), safety, and tolerability of single doses of once-daily USL255, Qudexy XR (topiramate) extended-release capsules, over a wide dosing range. Two single-dose, phase I studies in healthy adults were used to evaluate the PK profile and maximum
Elizabeth M Kelly et al.
Journal of managed care pharmacy : JMCP, 19(8), 642-654 (2013-10-01)
Obesity may lead to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Over a half billion adults worldwide are affected by obesity, and more than two-thirds of adults are either obese or overweight
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持